J&J faces South African competition probe over high tuberculosis drug prices
South Africa’s Competition Commission is set to probe Johnson & Johnson amid claims that the Big Pharma is charging the nation more than double than the rest of the world for its tuberculosis drug bedaquiline.
In a briefing hosted by the Health Justice Initiative (HJI) and other health advocacy groups, HJI founder Fatima Hassan said the investigation would look at whether J&J’s exclusion of patents violated South African competition law.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.